-
Innovation Ranking
NewInnovation Ranking – D-Link Corporation
D-Link Corp (DLC) is a communications and internet company in Taiwan. It designs, manufactures, and markets home surveillance, home networking, home automation, wireless, switching, surveillance, and network security products. It also offers accessories such as USB hubs; and network infrastructure solutions such as copper and fiber solutions. DLC provides its consumer, business solutions, and service provider solutions to digital home consumers, small office professionals, small-to-medium-sized businesses, and enterprise environments. It also offers various service provider solutions including home network solutions,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Lonafarnib in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lonafarnib in Hepatitis D report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lonafarnib in Hepatitis D Drug Details: Lonafarnib (Zokinvy) is a synthetic tricyclic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ropeginterferon Alfa-2B LA in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropeginterferon Alfa-2B LA in Hepatitis D report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropeginterferon Alfa-2B LA in Hepatitis D Drug Details: Ropeginterferon...
-
Product Insights
Hepatitis D – Drugs In Development, 2023
Global Markets Direct’s, ‘Hepatitis D - Drugs In Development, 2023’, provides an overview of the Hepatitis D pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Complement Factor D – Drugs In Development, 2023
Global Markets Direct’s Complement Factor D provides in depth analysis on Complement Factor D targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Complement Factor D targeted therapeutics...
-
Product Insights
Vitamin D Deficiency Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Vitamin D Deficiency Disorders - Drugs In Development, 2023’, provides an overview of the Vitamin D Deficiency Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vitamin D Deficiency Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Vascular Endothelial Growth Factor D – Drugs In Development, 2023
Global Markets Direct’s Vascular Endothelial Growth Factor D provides in depth analysis on Vascular Endothelial Growth Factor D targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Vascular...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Daplusiran in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daplusiran in Hepatitis D report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daplusiran in Hepatitis D Drug Details: JNJ-3989 (ARO-HBV) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Hepalatide in Hepatitis D
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Hepalatide in Hepatitis D report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hepalatide in Hepatitis D Drug Details: Synthetic Peptide (L-47) is under development...
-
Product Insights
NKG2 D Type II Integral Membrane Protein – Drugs In Development, 2023
Global Markets Direct’s NKG2 D Type II Integral Membrane Protein provides in depth analysis on NKG2 D Type II Integral Membrane Protein targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...